Omabit

United StatesBiology data and toolsSan Francisco, United StatesPrivate

Software that analyses a drug developer's own preclinical, clinical and genomic data alongside published research: a scientist chooses the question in plain language and it runs the analysis and writes it up, starting with clinical development, biomarker and translational teams.

Disclosed total$2M

Rounds on record1

Latest round$2MSeed · 2026-10-27

Last stated valuationNone stated

Investors named1

Research on recordNone yet

Money and evidence

Closed round

No research by this company is on the record yet.

Rounds and research, on one timeline

2026-10-27Seed
Round
$2M
For: continued platform development and more scientific and engineering staff
Models and platformHiring
The company's Business Wire release, read through FinancialContent's copy; the company's own news post says the same. The team building Omabit is called Hidden Pieces in the company's StartX post.
Lead · Bright Ventures
On the deal: Lenore Champagne Beirne (Founder and Managing Partner; spoke for the lead in the announcement, Bright Ventures)
Announced by the company · financialcontent.com ↗On the timeline →

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →